৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Indications
Linax-E tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Pharmacology
Linagliptin inhibits DPP-4 enzyme which declines the incretin hormones glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropie polypeptide (GIP). Linagliptin increases the concentrations of
active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glueagon. Both ineretin hormones are involved in the physiological regulation of glucose
homeostasis. Incretin horones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin blosynthesis and secretion from pancreatic beta
cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatie alpha cells, resulting in a reduction in hepatie glucose output.
Empagliftozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the predominant transporter responsible for reabsorption of glucose from kidney back into the circulation. By inhibiting SGLT2,
Empaglifiozin reduces renal reabsorption of fltered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Dosage & Administration
Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily, taken in the moming, with or without food.
Inereased dose: Dose may be increased to 25 mg Empagliflozin and 5 mg Linagliptin once daily.
Renal impaired patients: Assess renal function before initiating this tablet. Do not initiate this tablet if eGFR is below 45 mL/min/173 m2.Discontinue taking this tablet it eGFR talls below 45 ml/min/173 m2
Interaction
Diureties: Coadministration of Empagliflozin with diureties resulted in increased urine volume and frequency of volds, which might enhance the potential for volume depletion.
Insulin or Insulin Secretagogues: Coadministration of Empagliflozin with Insulin or Insulin secretagogues inereases the risk for hypoglycemia.
Inducers of P-glycoprotein or CYP3A4 Enzymes: Rifampin decreased Linagliptin exposure, suggesting that the efficacy of Linagliptin may be reduced when administered in combination with a strong P-gp or
CYP3A4 inducer.
Positive Urine Glucose Test: SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.
Inducers of P-glycoprotein or CYP3A4 Enzymes: Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or
CYP3A4 inducer.
Contraindications
. Severe renal impairment, end-stage renal disease, or dialysis
History of hypersensitivity reaction to Linagliptin, such as anaphylaxis, angloedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
. History of serious hypersensitivity reaction to Empagliflozin
.
Side Effects
The following important adverse reactions are described below and elsewhere in the labeling: Pancreatitis,






N/A
N/A




